Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparación del tratamiento estándar de atención con una combinación triple de agentes inmunoterapéuticos dirigidos

21 de octubre de 2026 actualizado por: National Cancer Institute (NCI)

Un ensayo aleatorizado de fase II de terapia triple (un inhibidor de PD-L1 Durvalumab (MEDI4736) en combinación con olaparib y cediranib) en comparación con olaparib y cediranib o durvalumab (MEDI4736) y cediranib o quimioterapia estándar de atención en mujeres con enfermedad epitelial recurrente resistente al platino Cáncer de ovario, cáncer primario de peritoneo o de Falopio que han recibido bevacizumab previo

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVE:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

II. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by overall survival (OS), as compared to physician's choice standard of care chemotherapy, in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer who had prior bevacizumab.

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on study. Patients also undergo collection of blood and computed tomography (CT) with contrast during screening, and CT or magnetic resonance imaging (MRI) scans throughout the trial.

ARM II: Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate orally (PO) once daily (QD) Monday through Friday, and olaparib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM III: Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

ARM IV: Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

After completion of study treatment, patients are followed up periodically for up to 5 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

120

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Estados Unidos
    • Alaska
      • Anchorage, Alaska, Estados Unidos, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, Estados Unidos, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, Estados Unidos, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, Estados Unidos, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, Estados Unidos, 99504
        • Anchorage Radiation Therapy Center
      • Fairbanks, Alaska, Estados Unidos, 99701
        • Fairbanks Memorial Hospital
    • Arizona
      • Goodyear, Arizona, Estados Unidos, 85338
        • CTCA at Western Regional Medical Center
      • Phoenix, Arizona, Estados Unidos, 85004
        • Cancer Center at Saint Joseph's
    • Arkansas
      • Fort Smith, Arkansas, Estados Unidos, 72903
        • Mercy Hospital Fort Smith
      • Hot Springs, Arkansas, Estados Unidos, 71913
        • CHI Saint Vincent Cancer Center Hot Springs
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Arroyo Grande, California, Estados Unidos, 93420
        • Mission Hope Medical Oncology - Arroyo Grande
      • Auburn, California, Estados Unidos, 95602
        • Sutter Auburn Faith Hospital
      • Auburn, California, Estados Unidos, 95603
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Berkeley, California, Estados Unidos, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burbank, California, Estados Unidos, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Cameron Park, California, Estados Unidos, 95682
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
      • Castro Valley, California, Estados Unidos, 94546
        • Eden Hospital Medical Center
      • Concord, California, Estados Unidos, 94520
        • John Muir Medical Center-Concord
      • Davis, California, Estados Unidos, 95616
        • Sutter Davis Hospital
      • Duarte, California, Estados Unidos, 91010
        • City of Hope Comprehensive Cancer Center
      • Fremont, California, Estados Unidos, 94538
        • Palo Alto Medical Foundation-Fremont
      • Lancaster, California, Estados Unidos, 93534
        • City of Hope Antelope Valley
      • Los Angeles, California, Estados Unidos, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Estados Unidos, 90033
        • Los Angeles General Medical Center
      • Modesto, California, Estados Unidos, 95355
        • Memorial Medical Center
      • Mountain View, California, Estados Unidos, 94040
        • Palo Alto Medical Foundation-Camino Division
      • Mountain View, California, Estados Unidos, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Palo Alto, California, Estados Unidos, 94301
        • Palo Alto Medical Foundation Health Care
      • Roseville, California, Estados Unidos, 95661
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville, California, Estados Unidos, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, Estados Unidos, 95816
        • Sutter Medical Center Sacramento
      • San Francisco, California, Estados Unidos, 94115
        • California Pacific Medical Center-Pacific Campus
      • San Luis Obispo, California, Estados Unidos, 93401
        • Pacific Central Coast Health Center-San Luis Obispo
      • Santa Cruz, California, Estados Unidos, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Maria, California, Estados Unidos, 93444
        • Mission Hope Medical Oncology - Santa Maria
      • Santa Rosa, California, Estados Unidos, 95403
        • Sutter Pacific Medical Foundation
      • South Pasadena, California, Estados Unidos, 91030
        • City of Hope South Pasadena
      • Sunnyvale, California, Estados Unidos, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Upland, California, Estados Unidos, 91786
        • City of Hope Upland
      • Vallejo, California, Estados Unidos, 94589
        • Sutter Solano Medical Center/Cancer Center
      • Walnut Creek, California, Estados Unidos, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Boulder, Colorado, Estados Unidos, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Centennial, Colorado, Estados Unidos, 80112
        • Rocky Mountain Cancer Centers - Centennial
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Rocky Mountain Cancer Centers-Penrose
      • Denver, Colorado, Estados Unidos, 80210
        • AdventHealth Porter
      • Durango, Colorado, Estados Unidos, 81301
        • Mercy Medical Center
      • Durango, Colorado, Estados Unidos, 81301
        • CommonSpirit Cancer Center Mercy
      • Lakewood, Colorado, Estados Unidos, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Estados Unidos, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Littleton, Colorado, Estados Unidos, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Longmont, Colorado, Estados Unidos, 80501
        • Longmont United Hospital
      • Longmont, Colorado, Estados Unidos, 80501
        • Rocky Mountain Cancer Centers-Longmont
      • Loveland, Colorado, Estados Unidos, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Estados Unidos, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Estados Unidos, 81004
        • Saint Mary Corwin Medical Center
    • Connecticut
      • Danbury, Connecticut, Estados Unidos, 06810
        • Danbury Hospital
      • Norwalk, Connecticut, Estados Unidos, 06856
        • Norwalk Hospital
    • Florida
      • Pensacola, Florida, Estados Unidos, 32504
        • Sacred Heart Hospital
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30342
        • Northside Hospital
      • Newnan, Georgia, Estados Unidos, 30265
        • CTCA at Southeastern Regional Medical Center
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Estados Unidos, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Estados Unidos, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Estados Unidos, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Estados Unidos, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Estados Unidos, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Estados Unidos, 83617
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, Estados Unidos, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Estados Unidos, 83642
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, Estados Unidos, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Estados Unidos, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Estados Unidos, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Estados Unidos, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, Estados Unidos, 62002
        • OSF Saint Anthony's Health Center
      • Aurora, Illinois, Estados Unidos, 60504
        • Rush-Copley Medical Center
      • Bloomington, Illinois, Estados Unidos, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Estados Unidos, 61520
        • Illinois CancerCare-Canton
      • Carbondale, Illinois, Estados Unidos, 62902
        • Memorial Hospital of Carbondale
      • Carterville, Illinois, Estados Unidos, 62918
        • SIH Cancer Institute
      • Carthage, Illinois, Estados Unidos, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Estados Unidos, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Estados Unidos, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Estados Unidos, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Estados Unidos, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Estados Unidos, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Estados Unidos, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Estados Unidos, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Estados Unidos, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Estados Unidos, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Estados Unidos, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, Estados Unidos, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Western Illinois Cancer Treatment Center
      • Galesburg, Illinois, Estados Unidos, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, Estados Unidos, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Estados Unidos, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Harvey, Illinois, Estados Unidos, 60426
        • Ingalls Memorial Hospital
      • Highland Park, Illinois, Estados Unidos, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, Estados Unidos, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Estados Unidos, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Estados Unidos, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Estados Unidos, 62864
        • SSM Health Good Samaritan
      • New Lenox, Illinois, Estados Unidos, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon, Illinois, Estados Unidos, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, Estados Unidos, 60462
        • University of Chicago Medicine-Orland Park
      • Ottawa, Illinois, Estados Unidos, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Estados Unidos, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Estados Unidos, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Estados Unidos, 61354
        • Valley Radiation Oncology
      • Princeton, Illinois, Estados Unidos, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Estados Unidos, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Estados Unidos, 62702
        • Springfield Clinic
      • Springfield, Illinois, Estados Unidos, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Estados Unidos, 61801
        • The Carle Foundation Hospital
      • Warrenville, Illinois, Estados Unidos, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, Estados Unidos, 61571
        • Illinois CancerCare - Washington
      • Yorkville, Illinois, Estados Unidos, 60560
        • Rush-Copley Healthcare Center
      • Zion, Illinois, Estados Unidos, 60099
        • Midwestern Regional Medical Center
    • Indiana
      • South Bend, Indiana, Estados Unidos, 46601
        • Memorial Hospital of South Bend
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Estados Unidos, 50010
        • McFarland Clinic - Ames
      • Boone, Iowa, Estados Unidos, 50036
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Estados Unidos, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Estados Unidos, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, Estados Unidos, 51503
        • Alegent Health Mercy Hospital
      • Creston, Iowa, Estados Unidos, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Estados Unidos, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Estados Unidos, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Estados Unidos, 50158
        • McFarland Clinic - Marshalltown
      • West Des Moines, Iowa, Estados Unidos, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Garden City, Kansas, Estados Unidos, 67846
        • Central Care Cancer Center - Garden City
      • Great Bend, Kansas, Estados Unidos, 67530
        • Central Care Cancer Center - Great Bend
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Corbin, Kentucky, Estados Unidos, 40701
        • Commonwealth Cancer Center-Corbin
      • Lexington, Kentucky, Estados Unidos, 40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington, Kentucky, Estados Unidos, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • London, Kentucky, Estados Unidos, 40741
        • CommonSpirit Saint Joseph Hospital London
      • Louisville, Kentucky, Estados Unidos, 40202
        • Jewish Hospital
      • Louisville, Kentucky, Estados Unidos, 40245
        • UofL Health Medical Center Northeast
      • Louisville, Kentucky, Estados Unidos, 40215
        • Saints Mary and Elizabeth Hospital
      • Shepherdsville, Kentucky, Estados Unidos, 40165
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70817
        • Our Lady of the Lake Medical Oncology
    • Maine
      • Augusta, Maine, Estados Unidos, 04330
        • Harold Alfond Center for Cancer Care
      • Brewer, Maine, Estados Unidos, 04412
        • Lafayette Family Cancer Center-EMMC
      • Scarborough, Maine, Estados Unidos, 04074
        • MaineHealth Maine Medical Center- Scarborough
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, Estados Unidos, 20892
        • National Institutes of Health Clinical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Rogel Cancer Center
      • Dearborn, Michigan, Estados Unidos, 48124
        • Corewell Health Dearborn Hospital
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Corewell Health William Beaumont University Hospital
      • Troy, Michigan, Estados Unidos, 48085
        • Corewell Health Beaumont Troy Hospital
    • Minnesota
      • Burnsville, Minnesota, Estados Unidos, 55337
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, Estados Unidos, 55337
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, Estados Unidos, 55008
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, Estados Unidos, 55433
        • Mercy Hospital
      • Edina, Minnesota, Estados Unidos, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, Estados Unidos, 55432
        • Unity Hospital
      • Maple Grove, Minnesota, Estados Unidos, 55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, Estados Unidos, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Estados Unidos, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Estados Unidos, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Estados Unidos, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Estados Unidos, 55454
        • Health Partners Inc
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota/Masonic Cancer Center
      • Monticello, Minnesota, Estados Unidos, 55362
        • Monticello Cancer Center
      • New Ulm, Minnesota, Estados Unidos, 56073
        • New Ulm Medical Center
      • Princeton, Minnesota, Estados Unidos, 55371
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, Estados Unidos, 55422
        • North Memorial Medical Health Center
      • Saint Louis Park, Minnesota, Estados Unidos, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Estados Unidos, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Estados Unidos, 55102
        • United Hospital
      • Shakopee, Minnesota, Estados Unidos, 55379
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, Estados Unidos, 55082
        • Lakeview Hospital
      • Waconia, Minnesota, Estados Unidos, 55387
        • Ridgeview Medical Center
      • Willmar, Minnesota, Estados Unidos, 56201
        • Rice Memorial Hospital
      • Woodbury, Minnesota, Estados Unidos, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming, Minnesota, Estados Unidos, 55092
        • Fairview Lakes Medical Center
    • Missouri
      • Ballwin, Missouri, Estados Unidos, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Bolivar, Missouri, Estados Unidos, 65613
        • Central Care Cancer Center - Bolivar
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Saint Francis Medical Center
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Farmington, Missouri, Estados Unidos, 63640
        • Parkland Health Center - Farmington
      • Jefferson City, Missouri, Estados Unidos, 65109
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, Estados Unidos, 64804
        • Freeman Health System
      • Joplin, Missouri, Estados Unidos, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Estados Unidos, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Estados Unidos, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • Heartland Regional Medical Center
      • Sainte Genevieve, Missouri, Estados Unidos, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, Estados Unidos, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Estados Unidos, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Estados Unidos, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Estados Unidos, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Estados Unidos, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Estados Unidos, 63080
        • Missouri Baptist Sullivan Hospital
      • Washington, Missouri, Estados Unidos, 63090
        • Mercy Hospital Washington
    • Montana
      • Anaconda, Montana, Estados Unidos, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Estados Unidos, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, Estados Unidos, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Estados Unidos, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Estados Unidos, 59804
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, Estados Unidos, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, Estados Unidos, 68847
        • CHI Health Good Samaritan
      • Lincoln, Nebraska, Estados Unidos, 68510
        • Saint Elizabeth Regional Medical Center
      • Lincoln, Nebraska, Estados Unidos, 68516
        • Cancer Partners of Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Estados Unidos, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Estados Unidos, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Estados Unidos, 68130
        • Alegent Health Lakeside Hospital
      • Papillion, Nebraska, Estados Unidos, 68046
        • Midlands Community Hospital
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Women's Cancer Center of Nevada
    • New Jersey
      • Neptune City, New Jersey, Estados Unidos, 07753
        • Jersey Shore Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • University of New Mexico Cancer Center
      • Las Cruces, New Mexico, Estados Unidos, 88011
        • Memorial Medical Center-Las Cruces
      • Rio Rancho, New Mexico, Estados Unidos, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Bay Shore, New York, Estados Unidos, 11706
        • Northwell Health Imbert Cancer Center
      • Brightwaters, New York, Estados Unidos, 11718
        • Island Gynecologic Oncology
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute
      • Lake Success, New York, Estados Unidos, 11042
        • Northwell Health/Center for Advanced Medicine
      • Syracuse, New York, Estados Unidos, 13210
        • State University of New York Upstate Medical University
      • White Plains, New York, Estados Unidos, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Clinton, North Carolina, Estados Unidos, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Southeastern Medical Oncology Center-Jacksonville
    • Ohio
      • Akron, Ohio, Estados Unidos, 44304
        • Summa Health System - Akron Campus
      • Alliance, Ohio, Estados Unidos, 44601
        • Aultman Alliance Community Hospital
      • Beachwood, Ohio, Estados Unidos, 44122
        • UHHS-Chagrin Highlands Medical Center
      • Belpre, Ohio, Estados Unidos, 45714
        • Strecker Cancer Center-Belpre
      • Canton, Ohio, Estados Unidos, 44710
        • Aultman Health Foundation
      • Centerville, Ohio, Estados Unidos, 45459
        • Miami Valley Hospital South
      • Chardon, Ohio, Estados Unidos, 44024
        • Geauga Hospital
      • Chillicothe, Ohio, Estados Unidos, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Estados Unidos, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Bethesda North Hospital
      • Cincinnati, Ohio, Estados Unidos, 45247
        • TriHealth Cancer Institute-Westside
      • Cincinnati, Ohio, Estados Unidos, 45255
        • TriHealth Cancer Institute-Anderson
      • Cleveland, Ohio, Estados Unidos, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Estados Unidos, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Estados Unidos, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Estados Unidos, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Estados Unidos, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Estados Unidos, 43228
        • Doctors Hospital
      • Columbus, Ohio, Estados Unidos, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Estados Unidos, 43215
        • Grant Medical Center
      • Columbus, Ohio, Estados Unidos, 43222
        • Mount Carmel Health Center West
      • Dayton, Ohio, Estados Unidos, 45409
        • Miami Valley Hospital
      • Delaware, Ohio, Estados Unidos, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Estados Unidos, 43015
        • Grady Memorial Hospital
      • Dublin, Ohio, Estados Unidos, 43016
        • Dublin Methodist Hospital
      • Gahanna, Ohio, Estados Unidos, 43230
        • Central Ohio Breast and Endocrine Surgery
      • Grove City, Ohio, Estados Unidos, 43123
        • Mount Carmel Grove City Hospital
      • Lancaster, Ohio, Estados Unidos, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Estados Unidos, 45801
        • Saint Rita's Medical Center
      • Mansfield, Ohio, Estados Unidos, 44903
        • OhioHealth Mansfield Hospital
      • Marietta, Ohio, Estados Unidos, 45750
        • Marietta Memorial Hospital
      • Marion, Ohio, Estados Unidos, 43302
        • OhioHealth Marion General Hospital
      • Mayfield Heights, Ohio, Estados Unidos, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, Estados Unidos, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, Estados Unidos, 43050
        • Knox Community Hospital
      • Newark, Ohio, Estados Unidos, 43055
        • Licking Memorial Hospital
      • Newark, Ohio, Estados Unidos, 43055
        • Newark Radiation Oncology
      • Perrysburg, Ohio, Estados Unidos, 43551
        • Mercy Health - Perrysburg Hospital
      • Portsmouth, Ohio, Estados Unidos, 45662
        • Southern Ohio Medical Center
      • Toledo, Ohio, Estados Unidos, 43623
        • Mercy Health - Saint Anne Hospital
      • Toledo, Ohio, Estados Unidos, 43608
        • Mercy Health - Saint Vincent Hospital
      • Wadsworth, Ohio, Estados Unidos, 44281
        • University Hospitals Sharon Health Center
      • Westerville, Ohio, Estados Unidos, 43081
        • Saint Ann's Hospital
      • Westlake, Ohio, Estados Unidos, 44145
        • UH Seidman Cancer Center at Saint John Medical Center
      • Zanesville, Ohio, Estados Unidos, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Lawton, Oklahoma, Estados Unidos, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Estados Unidos, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Baker City, Oregon, Estados Unidos, 97814
        • Saint Alphonsus Cancer Care Center-Baker City
      • Bend, Oregon, Estados Unidos, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Estados Unidos, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Estados Unidos, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, Estados Unidos, 97420
        • Bay Area Hospital
      • Newberg, Oregon, Estados Unidos, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Estados Unidos, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Estados Unidos, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Portland, Oregon, Estados Unidos, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Estados Unidos, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, Estados Unidos, 97756
        • Saint Charles Health System-Redmond
      • Tualatin, Oregon, Estados Unidos, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Butler, Pennsylvania, Estados Unidos, 16001
        • UPMC Hillman Cancer Center at Butler Health System
      • Erie, Pennsylvania, Estados Unidos, 16505
        • UPMC Hillman Cancer Center Erie
      • Paoli, Pennsylvania, Estados Unidos, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Estados Unidos, 19114
        • Jefferson Torresdale Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • West Penn Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • UPMC-Magee Womens Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15237
        • UPMC-Passavant Hospital
      • Willow Grove, Pennsylvania, Estados Unidos, 19090
        • Asplundh Cancer Pavilion
      • Wynnewood, Pennsylvania, Estados Unidos, 19096
        • Lankenau Medical Center
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02905
        • Women and Infants Hospital
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina
      • Greenville, South Carolina, Estados Unidos, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57701
        • Rapid City Regional Hospital
    • Tennessee
      • Bristol, Tennessee, Estados Unidos, 37620
        • Bristol Regional Medical Center
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Knoxville, Tennessee, Estados Unidos, 37916
        • Covenant Health Cancer Centers
      • Knoxville, Tennessee, Estados Unidos, 37932
        • Covenant Health Cancer Centers - West
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Estados Unidos, 37204
        • Vanderbilt Breast Center at One Hundred Oaks
    • Texas
      • Bryan, Texas, Estados Unidos, 77802
        • Saint Joseph Regional Cancer Center
      • Dallas, Texas, Estados Unidos, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Estados Unidos, 77070
        • Methodist Willowbrook Hospital
      • Houston, Texas, Estados Unidos, 77094
        • Houston Methodist West Hospital
      • Sugar Land, Texas, Estados Unidos, 77479
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, Estados Unidos, 77385
        • Houston Methodist The Woodlands Hospital
    • Virginia
      • Bristol, Virginia, Estados Unidos, 24201
        • Ballad Health Cancer Care - Bristol
      • Norton, Virginia, Estados Unidos, 24273
        • Ballad Health Cancer Care - Norton
    • Washington
      • Aberdeen, Washington, Estados Unidos, 98520
        • Providence Regional Cancer System-Aberdeen
      • Bellingham, Washington, Estados Unidos, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, Estados Unidos, 98166
        • Saint Anne Hospital
      • Centralia, Washington, Estados Unidos, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, Estados Unidos, 98026
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, Estados Unidos, 98022
        • Saint Elizabeth Hospital
      • Everett, Washington, Estados Unidos, 98201
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, Estados Unidos, 98003
        • Saint Francis Hospital
      • Issaquah, Washington, Estados Unidos, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, Estados Unidos, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, Estados Unidos, 98503
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, Estados Unidos, 98499
        • Saint Clare Hospital
      • Longview, Washington, Estados Unidos, 98632
        • PeaceHealth Saint John Medical Center
      • Port Townsend, Washington, Estados Unidos, 98368
        • Jefferson Healthcare
      • Seattle, Washington, Estados Unidos, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, Estados Unidos, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, Estados Unidos, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, Estados Unidos, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, Estados Unidos, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, Estados Unidos, 98584
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, Estados Unidos, 98383
        • Saint Joseph Medical Center Hematology and Oncology - Silverdale
      • Tacoma, Washington, Estados Unidos, 98405
        • Franciscan Research Center-Northwest Medical Plaza
      • Vancouver, Washington, Estados Unidos, 98686
        • Legacy Salmon Creek Hospital
      • Vancouver, Washington, Estados Unidos, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, Estados Unidos, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yelm, Washington, Estados Unidos, 98597
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Charleston, West Virginia, Estados Unidos, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Green Bay, Wisconsin, Estados Unidos, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, Estados Unidos, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin
      • Mukwonago, Wisconsin, Estados Unidos, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Estados Unidos, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Estados Unidos, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, Estados Unidos, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Sturgeon Bay, Wisconsin, Estados Unidos, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Waukesha, Wisconsin, Estados Unidos, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, Estados Unidos, 53188
        • ProHealth Waukesha Memorial Hospital
    • Wyoming
      • Cody, Wyoming, Estados Unidos, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Estados Unidos, 82801
        • Welch Cancer Center
  • Puerto Rico
      • Bayamón, Puerto Rico, 00959-5060
        • Cancer Center-Metro Medical Center Bayamon
      • Caguas, Puerto Rico, 00726
        • HIMA San Pablo Oncologic Hospital
      • Manati, Puerto Rico, 00674
        • Doctors Cancer Center
      • Ponce, Puerto Rico, 00716
        • Instituto Oncologia Moderna Ponce
      • San Juan, Puerto Rico, 00917
        • San Juan Community Oncology Group
      • San Juan, Puerto Rico, 00927
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Puerto Rico, 00936
        • San Juan City Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy. The date should be calculated from the last administered dose of platinum therapy

  • Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma based on local histopathological findings. Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, or mucinous carcinoma histologies are also eligible, provided that the patient has a known deleterious BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Histologic confirmation of the original primary tumor is required via the pathology report (upload of report required). Confirmation of BRCA1 and BRCA2 germline and/or somatic mutation status and hormone receptor (HR) status is required for all entered patients (if available) via testing report (upload of report[s] required)

  • Evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a CA125 >= 2 x upper limit of normal [ULN])

  • Prior therapy:

    • At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
    • Prior use of bevacizumab in the upfront or recurrent setting is required.
    • Prior use of PARP inhibitor is allowed.
    • Prior use of immune checkpoint blockade (e.g., a PD-L1/PD-1inhibitor or a CTLA-4 inhibitor) is allowed

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

  • Absolute neutrophil count (ANC) >= 1,500/mcL

  • Hemoglobin >= 10 g/dL

  • Platelets >= 100,000/mcL

  • Creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR) of > 50 mL/min estimated using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR)

  • Urine protein: creatinine ratio (UPC) of =< 1

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

  • Age >= 18 years

  • Body weight > 30 kg

  • Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on a maximum of three antihypertensive medications. Patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to study registration. It is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol. Patients must be willing and able to check and record daily blood pressure readings. BP cuffs will be provided to patients randomized to the cediranib-containing arms

  • Adequately controlled thyroid dysfunction with no symptoms of thyroid dysfunction and normal thyroid stimulating hormone (TSH). If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required

  • Able to swallow and retain oral medications and no gastrointestinal (GI) illnesses that would preclude absorption of olaparib and cediranib as judged by treating physician

  • Toxicities of prior therapy (excepting alopecia and vitiligo), should be resolved to less than or equal to grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

  • Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence). Note: Definition of women of no longer having childbearing potential: Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of study treatment. Postmenopausal is defined as: Age >= 60 years, or age < 60 with any one or more of the conditions below:

    • Amenorrhoeic for >= 1 year in the absence of chemotherapy and/or hormonal treatments,
    • Luteinizing hormone and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range,
    • Radiation-induced oophorectomy with last menses > 1 year ago,
    • Chemotherapy-induced menopause with > 1 year interval since last menses,
    • Surgical sterilization (bilateral oophorectomy or hysterectomy)

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information

Exclusion Criteria:

  • Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy

  • Rising CA-125 only without RECIST 1.1 evaluable disease

  • Prior therapy:

    • Patients who have had chemotherapy, investigational drugs or radiotherapy within 3 weeks prior to study registration or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.

    • Patients may not have had hormonal therapy within 2 weeks of study registration. Patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions.

    • Prior use of concurrent olaparib and cediranib combination.

    • Patients who have experienced immune-mediated adverse events requiring dose modification or discontinuation.

    • For patients who have received prior PARP inhibitor:

      • Patients who have required dose modification or dose reduction of olaparib will not be eligible, as they will not be able to start this study at full dose.
      • Patients who have required dose reduction of non-olaparib PARP inhibitors for hematologic adverse events will not be eligible (Note: niraparib that is initiated at 200mg daily per weight and platelet guidelines is not considered a dose reduction).
      • Patients who required dose-reduction of non-olaparib PARP inhibitors for non-hematologic adverse events may be eligible after discussion with the Study Chair if the treating investigator feels that they could appropriately receive olaparib at full dose.

  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to study registration

  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months of study registration except temporary (< 24 hr) improved with medical management, within last 3 months

  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1

  • Dependency on IV hydration or total parenteral nutrition (TPN)

  • Pregnant women. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events. Patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study registration

  • Patients who have the following clinical conditions are considered to be at increased risk for cardiac toxicities. Patients with any cardiac history of the following conditions:

    • History of myocardial infarction or myocarditis within six months of study registration
    • Unstable angina
    • Resting electrocardiogram (ECG) with clinically significant abnormal findings.
    • New York Heart Association functional classification of III or IV

  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines. Patients with the following risk factors should have a baseline cardiac function assessment:

    • Prior treatment with anthracyclines
    • Prior treatment with trastuzumab or T-DM1
    • Prior central thoracic radiation therapy (RT), including RT to the heart
    • History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
    • Prior history of impaired cardiac function

  • History of stroke or transient ischemic attack within six months of study registration

  • Clinically significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)

  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. Patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment. Note: Local surgery of isolated lesions for palliative intent is acceptable

  • Evidence of coagulopathy or bleeding diathesis. Therapeutic anticoagulation for prior thromboembolic events, including warfarin, is permitted. Patients receiving warfarin are recommended to have careful monitoring of international normalized ratio (INR)

  • Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)

  • Human immunodeficiency virus (HIV) positive patients due to potential drug and drug interactions

  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments

  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events or compromise the ability of the patient to given written informed consent

  • Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4. Dihydropyridine calcium-channel blockers are permitted for management of hypertension

  • Current or prior use of immunosuppressive medication within 14 days of study registration. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab, olaparib, or cediranib

  • Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) ribonucleic acid (RNA)

  • Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))

Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Droga: Paclitaxel

Given IV

Otros nombres:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Procedimiento: Computed Tomography

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico
Procedimiento: Magnetic Resonance Imaging

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural
Procedimiento: Echocardiography Test

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE
Procedimiento: Multigated Acquisition Scan

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV
Procedimiento: Biospecimen Collection

Undergo collection of blood

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras
Droga: Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Otros nombres:
  • ATI-0918
  • Caelyx
  • Doxil
  • Doxilen
  • Liposoma de doxorrubicina HCl
  • Duomeisu
  • Evacet
  • Lipodox
  • Adriamicina liposomal
  • Doxorrubicina encapsulada en liposomas
  • Liposoma de clorhidrato de doxorrubicina pegilada
  • Doxorrubicina S-liposomal
  • Doxorrubicina liposomal Stealth
  • TLC D-99
  • Dox-SL
  • Doxorrubicina HCl Liposomal
  • Liposoma de clorhidrato de doxorrubicina
  • Lipodox 50
  • Clorhidrato de doxorrubicina liposomal
  • Doxorrubicina liposomal pegilada
  • Doxorrubicina liposomal
Droga: Topotecan Hydrochloride

Given IV

Otros nombres:
  • Hycamtin
  • Hicamptamina
  • SKF S-104864-A
  • Clorhidrato de topotecán
  • clorhidrato de topotecán (oral)
  • Potactasol
  • Evotopina
  • Topotec
  • Clorhidrato de nogitecán
  • SKF S 104864 A
  • SKF S104864A
Procedimiento: Computed Tomography with Contrast

Undergo CT with contrast

Otros nombres:
  • Tomografía computarizada con contraste mejorado
  • EXPLORACIÓN POR TC CON CONTRASTE MEJORADO
  • Tomografía computarizada mejorada con contraste
  • Tomografía computarizada con contraste
  • TC con contraste
Experimental: Arm II (durvalumab, cediranib maleate, olaparib)

Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedimiento: Computed Tomography

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico
Procedimiento: Magnetic Resonance Imaging

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural
Procedimiento: Echocardiography Test

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE
Procedimiento: Multigated Acquisition Scan

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV
Procedimiento: Biospecimen Collection

Undergo collection of blood

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras
Droga: Cediranib Maleate

Given PO

Otros nombres:
  • AZD2171
  • AZD2171 Maleato
  • Recientes
Droga: Olaparib

Given PO

Otros nombres:
  • Lynparza
  • MXN 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Inhibidor PARP AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Procedimiento: Computed Tomography with Contrast

Undergo CT with contrast

Otros nombres:
  • Tomografía computarizada con contraste mejorado
  • EXPLORACIÓN POR TC CON CONTRASTE MEJORADO
  • Tomografía computarizada mejorada con contraste
  • Tomografía computarizada con contraste
  • TC con contraste
Biológico: Durvalumab

Given IV

Otros nombres:
  • Imfinzi
  • Inmunoglobulina G1, anti-(proteína humana B7-H1) (cadena pesada monoclonal humana MEDI4736), disulfuro con cadena kappa monoclonal humana MEDI4736, dímero
  • MEDI-4736
  • MEDI4736
  • MEDIO 4736
Experimental: Arm III (durvalumab, cediranib maleate)

Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedimiento: Computed Tomography

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico
Procedimiento: Magnetic Resonance Imaging

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural
Procedimiento: Echocardiography Test

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE
Procedimiento: Multigated Acquisition Scan

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV
Procedimiento: Biospecimen Collection

Undergo collection of blood

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras
Droga: Cediranib Maleate

Given PO

Otros nombres:
  • AZD2171
  • AZD2171 Maleato
  • Recientes
Procedimiento: Computed Tomography with Contrast

Undergo CT with contrast

Otros nombres:
  • Tomografía computarizada con contraste mejorado
  • EXPLORACIÓN POR TC CON CONTRASTE MEJORADO
  • Tomografía computarizada mejorada con contraste
  • Tomografía computarizada con contraste
  • TC con contraste
Biológico: Durvalumab

Given IV

Otros nombres:
  • Imfinzi
  • Inmunoglobulina G1, anti-(proteína humana B7-H1) (cadena pesada monoclonal humana MEDI4736), disulfuro con cadena kappa monoclonal humana MEDI4736, dímero
  • MEDI-4736
  • MEDI4736
  • MEDIO 4736
Experimental: Arm IV (cediranib maleate, olaparib)

Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
Procedimiento: Computed Tomography

Undergo CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico
Procedimiento: Magnetic Resonance Imaging

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural
Procedimiento: Echocardiography Test

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE
Procedimiento: Biospecimen Collection

Undergo collection of blood

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras
Droga: Cediranib Maleate

Given PO

Otros nombres:
  • AZD2171
  • AZD2171 Maleato
  • Recientes
Droga: Olaparib

Given PO

Otros nombres:
  • Lynparza
  • MXN 2281
  • AZD-2281
  • AZD2281
  • KU-0059436
  • Inhibidor PARP AZD2281
  • KU0059436
  • Olanib
  • Olaparix
  • KU 0059436
Procedimiento: Computed Tomography with Contrast

Undergo CT with contrast

Otros nombres:
  • Tomografía computarizada con contraste mejorado
  • EXPLORACIÓN POR TC CON CONTRASTE MEJORADO
  • Tomografía computarizada mejorada con contraste
  • Tomografía computarizada con contraste
  • TC con contraste

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression Free Survival
Periodo de tiempo: From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

The relationship of randomized treatment assignment to progression free survival. The RECIST 1.1 criteria are used for disease progression. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate
Periodo de tiempo: From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Determination of response should take into consideration all target and non-target lesions. Here are the definitions of CR, PR, PD and SD: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters (i.e. the nadir) while on study. The CI is the Jeffreys interval.
From the start of the treatment until disease progression/recurrence, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Duration of Response
Periodo de tiempo: Throughout study treatment, up to 10.6 months.

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. Duration of response was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first.

Per RECIST, Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as an >=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Reporting the number of months from complete or partial response until disease progression, death or censoring, whichever occurs first. In the absence of disease progression or death, censoring time is based on date of last CT scan.
Throughout study treatment, up to 10.6 months.
Overall Survival
Periodo de tiempo: Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Overall survival will be presented by Kaplan Meier methods. Overall Survival (OS) is defined as the duration of time from study entry to date of death from any cause. A subject who has not died will be censored on the date that they were last known to be alive.
Time from study entry to date of death from any cause, or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.
Count of Participants With a Grade 3 (or Higher) Adverse Event
Periodo de tiempo: From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

The number of patients (in each reporting group) who experienced a grade 3 (or higher) adverse event
From the start of treatment until disease progression/recurrence or termination by the DMC. The median followup time was 4.3 months. The maximum followup time was 11 months. Patients are no longer being assessed.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

National Cancer Institute (NCI)

Colaboradores

NRG Oncology

Investigadores

  • Investigador principal: Jung-min Lee, NRG Oncology

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de junio de 2021

Finalización primaria (Actual)

26 de enero de 2023

Finalización del estudio (Estimado)

25 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de febrero de 2021

Primero enviado que cumplió con los criterios de control de calidad

4 de febrero de 2021

Publicado por primera vez (Actual)

5 de febrero de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de octubre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • NCI-2021-00615
  • U10CA180868 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2021-00615 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • NRG-GY023 (Otro identificador: CTEP)
  • NRG-GY023 (Otro identificador: NRG Oncology)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir